KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gilead Sciences (GILD) Operating Income (2016 - 2025)

Gilead Sciences' Operating Income history spans 17 years, with the latest figure at $2.0 billion for Q4 2025.

  • For Q4 2025, Operating Income fell 19.09% year-over-year to $2.0 billion; the TTM value through Dec 2025 reached $10.0 billion, up 503.01%, while the annual FY2025 figure was $10.0 billion, 503.01% up from the prior year.
  • Operating Income reached $2.0 billion in Q4 2025 per GILD's latest filing, down from $3.3 billion in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $3.8 billion in Q3 2021 to a low of -$4.3 billion in Q1 2024.
  • Average Operating Income over 5 years is $1.8 billion, with a median of $2.2 billion recorded in 2021.
  • Peak YoY movement for Operating Income: skyrocketed 765.48% in 2023, then plummeted 353.49% in 2024.
  • A 5-year view of Operating Income shows it stood at $940.0 million in 2021, then skyrocketed by 141.17% to $2.3 billion in 2022, then decreased by 28.89% to $1.6 billion in 2023, then surged by 52.11% to $2.5 billion in 2024, then decreased by 19.09% to $2.0 billion in 2025.
  • Per Business Quant, the three most recent readings for GILD's Operating Income are $2.0 billion (Q4 2025), $3.3 billion (Q3 2025), and $2.5 billion (Q2 2025).